MissionTEC

Study case

Parathyroid Hormone

By supporting this study, MissionTEC has enabled a considerable increase recruitment and a higher retention rate.

The context

The purpose of this phase I study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of NEW-3601, a synthetic parathyroid hormone. It is being conducted in healthy volunteers and patients with hypoparathyroidism (HP).

MissionTEC has been mandated to carry out the necessary tasks for the follow-up of the study in the patients' homes.

MissionTEC's role

Thanks to its large network of research nurses and site coordinators, the MissionTEC teams were able to carry out the following missions in the patients' homes :

- Taking blood samples
- Taking vital signs
- Subcutaneous administration of NEW-3601



The objectives

- To evaluate the safety and tolerability of NEW-3601 after subcutaneous administration over 4 weeks (HP patients)
- To evaluate the safety and tolerability of NEW-3601 after subcutaneous administration over 2 months (HP patients)

Key figures

3
Countries of intervention

2
Patient cohorts

10 to 12
Clinical centres in Europe

24
Study participants

Centre Pierre Potier, 1 place Pierre Potier, Oncopole entrée B 31100 Toulouse (France)

+33 5 31 61 57 30
+33 1 80 90 50 80

www.mission-tec.com

contact@mission-tec.com